(Reuters) - Food and Drug Administration staff raised five issues with GPC's application for the drug Orplatna, known generically as satraplatin. Among them, they asked whether one of the main goals in a GPC study was acceptable for marketing approval, and whether pain measurements were reliable.
Read more at Reuters.com Government Filings News
Read more at Reuters.com Government Filings News
No comments:
Post a Comment